Adult Immunization Schedule Addendum (Addendum updated June 27, 2024)

Recommendations for Ages 19 Years or Older, United States, 2024

Purpose

Outline new or updated vaccine recommendations that have occurred since October 26, 2023.

How to use the schedule

Vaccines in the Adult Immunization Schedule

To make vaccination recommendations, healthcare providers should:

  1. Determine recommended vaccine by age (Table 1 - By Age)
  2. Assess need for additional recommended vaccinations by medical condition or other indication (Table 2 - By Medical Condition)
  3. Review vaccine types, dosing frequencies and intervals, and considerations for special situations (Notes)
  4. Review contraindications and precautions for vaccine types (Appendix)
  5. Review new or updated ACIP guidance (Addendum)

Addendum

In addition to the recommendations presented in the previous sections of this immunization schedule, ACIP has approved the following recommendations by majority vote since October 26, 2023. The following recommendations have been adopted by the CDC Director and are now official. Links are provided if these recommendations have been published in Morbidity and Mortality Weekly Report (MMWR).

Vaccines Recommendations Effective Date of Recommendation*
COVID
  • ACIP recommends persons ≥65 years of age should receive an additional dose of 2023–2024 Formula COVID-19 vaccine.
  • For detailed information, see: www.cdc.gov/covidschedule
 February 28, 2024
COVID-19 (Moderna,
Pfizer-BioNTech, Novavax)		 ACIP recommends 2024-2025 COVID-19 vaccines as authorized or approved by FDA in persons ≥6 months of age. June 27, 2024
Influenza
  • ACIP reaffirms the recommendation for routine annual influenza vaccination of all persons aged ≥6 months who do not have contraindications.
  • ACIP recommends high-dose inactivated (HD-IIV3) and adjuvanted inactivated (aIIV3) influenza vaccines as acceptable options for influenza vaccination of solid organ transplant recipients aged 18 through 64 years who are on immunosuppressive medication regimens, without a preference over other age-appropriate IIV3s or RIV3.
 June 27, 2024
Pneumococcal conjugate vaccine ACIP recommends PCV21 as an option for adults aged ≥19 years who currently have a recommendation to receive a dose of PCV. June 27, 2024
Respiratory syncytial virus vaccine (RSV)
  • ACIP recommends adults 75 years of age and older receive a single dose of RSV vaccine.a,b
  • ACIP recommends adults 60–74 years of age and older who are at increased risk of severe RSV disease receive a single dose of RSV vaccine.a,b

a RSV vaccination is recommended as a single lifetime dose only. Persons who have already received RSV vaccination are NOT recommended to receive another dose.

b These recommendations supplant the current recommendation that adults 60 years of age and older may receive RSV vaccination, using shared clinical decision-making. Adults 60–74 years of age who are not at increased risk of severe RSV disease are NOT recommended to receive RSV vaccination.

CCDC will publish Clinical Considerations that describe chronic medical conditions and other risk factors for severe RSV disease for use in this risk-based recommendation.

 June 26, 2024

*The effective date is the date when the CDC director adopted the recommendation and when the ACIP recommendation became official.

Print
Content Source:
National Center for Immunization and Respiratory Diseases